1,6-anhydro-3,4-dideoxyhex-3-enopyran-2-ulose: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 699486 |
| CHEMBL ID | 4126941 |
| CHEBI ID | 30999 |
| SCHEMBL ID | 7155405 |
| MeSH ID | M0501086 |
| Synonym |
|---|
| 6,8-dioxabicyclo(3.2.1)oct-2-en-4-one, (1s)- |
| brn 4859778 |
| ccris 4274 |
| 37112-31-5 |
| CHEBI:30999 |
| (1s)-6,8-dioxabicyclo(3.2.1)oct-2-en-4-one |
| levoglucosenone |
| (1s,5r)-6,8-dioxabicyclo[3.2.1]oct-2-en-4-one |
| 1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyranos-2-ulose |
| (1s)-6,8-dioxabicyclo[3.2.1]oct-2-en-4-one |
| AKOS006345460 |
| 1,6-anhydro-3,4-dideoxyhex-3-enopyran-2-ulose |
| b7n23sn1lb , |
| unii-b7n23sn1lb |
| 1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose |
| SCHEMBL7155405 |
| L0150 |
| HITOXZPZGPXYHY-UJURSFKZSA-N |
| PS-4213 |
| W-202534 |
| levoglucosenone [mi] |
| 1,6-anhydro-3,4-dideoxy-.beta.-d-glycero-hex-3-enopyranos-2-ulose |
| levoglucosenone, (-)- |
| 6,8-dioxabicyclo(3.2.1)oct-2-en-4-one, (1s,5r)- |
| 1,6-anhydro-3,4-dideoxy-.delta.3-.beta.-d-pyranosen-2-one |
| levoglucosenone, >=95% (gc) |
| BCP07825 |
| Q27114054 |
| chembl4126941 , |
| bdbm50276378 |
| BB 0322953 |
| T72379 |
| A856725 |
| 6,8-dioxabicyclo3.2.1oct-2-en-4-one, (1s,5r)- |
| CS-0016272 |
| HY-21226 |
| Class | Description |
|---|---|
| anhydrohexose | Any anhydro sugar formally arising by elimination of water from two hydroxy groups of a single molecule of a hexose or hexose derivative. |
| deoxyketohexose | Any ketohexose having at least one hydroxy group replaced by hydrogen. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 (µMol) | 1.2000 | 0.0004 | 1.4419 | 10.0000 | AID1498932 |
| NACHT, LRR and PYD domains-containing protein 3 | Homo sapiens (human) | IC50 (µMol) | 6.6000 | 0.0050 | 2.1804 | 10.0000 | AID1498934 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1498932 | Inhibition of nigericin-induced NLRP3 inflammasome activation in C57BL/6 mouse bone marrow derived macrophages assessed as reduction in LPS-stimulated IL-1beta secretion incubated for 1 hr followed by nigericin addition measured after 1 hr by ELISA | 2018 | Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13 | Synthesis of 1,5-Anhydro-d-fructose derivatives and evaluation of their inflammasome inhibitors. |
| AID1636613 | Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines. |
| AID1636614 | Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines. |
| AID1498934 | Inhibition of nigericin-induced NLRP3 inflammasome activation in PMA-differentiated human THP1 cells assessed as reduction in LPS-stimulated IL-1beta secretion incubated for 1 hr prior to stimulation with nigericin for 1 hr by quanti-blue based SEAP repor | 2018 | Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13 | Synthesis of 1,5-Anhydro-d-fructose derivatives and evaluation of their inflammasome inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| The oxidative induction of DNA lesions in cancer cells by 5-thio-d-glucose and 6-thio-d-fructopyranose and their genotoxic effects. Part 3. Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue: 5 | 2017 |
| Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines. Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue: 16 | 2016 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |